STRATEGY FOR DESIGN OF ANTISTAPHYLOCOCCAL DRUGS FOR IMMUNOPROPHYLAXIS AND IMMUNOTHERAPY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Numerous efforts by a number of research organizations to design staphylococcus vaccines have been unsuccessful to this day and there are virtually unavailable effective commercial immunopreparations to control staphylococcal infections. The review presents the results of trials of vaccines designed using the major virulence factors of Staphylococcus aureus. Foremost, these are capsular polysaccharides, alpha-toxin, leukocidin, and surface protein antigens. During the clinical trials, the vaccines based on these antigens proved to be insuff iciently effective; in this connection, a start was made to develop polyvalent vaccines by choosing protective antigens. These vaccines were designed on the basis of surface proteins, including iron-regulated ones. There are also attempts to develop vaccines based on polysaccharide-protein compositions obtained from specially selected S.aureus strains. Virtually all multivalent vaccines are passing a clinical stage or phase 1 clinical trial now. To select S. aureus strains and to choose protective antigens are an important condition for preparing an effective staphylococcal vaccine; these have been used to design the vaccine developed at the I.I. Mechnikov Research Institute for Vaccines and Sera, Russian Academy of Medical Sciences.

全文:

受限制的访问

作者简介

Irina GRUBER

I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences

Email: igruber_instmech@mail.ru

N. EGOROVA

I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences

E. KURBATOVA

I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences

Email: kurbatova6162@yandex.ru

N. MIKHAILOVA

I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences

Email: n_michailova@inbox.ru

参考

  1. Национальная концепция профилактики инфекций, связанных с оказанием медицинской помощи. Утверждена руководителем Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека, Главным государственным санитарным врачом РФ Г.Г. Онищенко 06.11.2011
  2. Кузьменко О.М., Грубер И.М., Прияткин Р.Г. Профилактика и иммунотерапия стафилококковых инфекций бактериальными вакцинами. Журн. микробиол. 2010; (5): 106-112.
  3. Johri A.K., Paoletti L.C., Glaser P., Dua M., Sharma P.K., Grandi G. et al. Group B Streptococcus: global incidence and vaccine development. Nat. Rev. Microbiol. 2006; 4(12): 932-942.
  4. O’Riordan K., Lee J.C. Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev. 2004; 17(1): 218-234.
  5. Fattom A.I., Sarwar J., Ortiz A., Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 1996; 64(5): 1659-1665.
  6. Lee J.C., Park J.S., Shepherd S.E., Carey V., Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. 1997; 65(10): 4146-4151.
  7. Shinefield H., Black S., Fattom A., Horwith G., Rasgon S., Ordonez J. et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 2002; 346(7): 491-496.
  8. Benjamin D.K., Schelonka R., White R., Holley H.P., Bifano E., Cummings J. et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol. 2006; 26(5): 290-295.
  9. Rupp M.E., Holley H.PJr., Lutz J., Dicpinigaitis P.V., Woods C.W., Levine D.P. et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal antiStaphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2007; 51(12): 4249-4254.
  10. Ruppitsch W., Stoger A., Schmid D., Fretz R., Indra A., Allerberger F. et al. Occurrence of the USA300 community-acquired Staphylococcus aureus clone in Austria. Euro Surveill. 2007; 12(10): E071025.1.
  11. Witte W., Strommenger B., Cuny C., Heuck D, Nuebel U. Methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leucocidin gene in Germany in 2005 and 2006. J. Antimicrob. Chemother. 2007; 60(6): 1258-1263.
  12. Schaffer A.C., Lee J.C. Staphylococcal vaccines and immunotherapies. Infect. Dis. Clin. North. Am. 2009; 23(1): 153-171.
  13. Otto M. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin. Biol. Ther. 2010; 10(7): 1049-1059. doi: 10.1517/14712598.2010.495115.
  14. Bubeck Wardenburg J., Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 2008; 205(2): 287-294.
  15. Lee S.S., Kim Y.J., Chung D.R., Jung K.S., Kim J.S. Invasive Infection Caused by Community-Associated Methicillin-Resistant Staphylococcus aureus Strain Not Carrying Panton-Valentine Leukocidin in Korea. J. Clin. Microbiol. 2009; 48(1): 311-313.
  16. Rollason J., Bastin L., Hilton A.C., Pillay D.G., Worthington T., McKeon C. et al. Epidemiology of community-acquired meticillin-resistant Staphylococcus aureus obtained from the UK West Midlands region. J. Hosp. Infect. 2008; 70(4): 314-320.
  17. Voyich J.M., Otto M., Mathema B, Braughton K.R, Whitney A.R., Welty D. et al. Is Panton-Valentine Leukocidin the Major Virulence Determinant in Community-Associated Methicillin-Resistant Staphylococcus aureus Disease? J. Infect. Dis. 2006; 194(12): 1761-1770.
  18. Brown E.L., Dumitrescu O., Thomas D., Badiou C., Koers E.M., Choudhury P. et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect. 2008; 15(2): 156-164.
  19. Bubeck Wardenburg J., Palazzolo-Ballance A.M., Otto M., Schneewind O., DeLeo F.R. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillinresistant Staphylococcus aureus disease. J. Infect. Dis. 2008; 198(8): 1166-1170.
  20. Diep B.A., Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol. 2008; 16(8): 361-369.
  21. Josefsson E., Hartford O., O’Brien L., Patti J.M., Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 2001; 184(12): 15721580.
  22. Medzhitov R., Janway Jr. C.A. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.
  23. Medzhitov R., Janway Jr.C.A. Innate immune induction of the adaptive immune response. Cold Spring. Harb. Symp. Quant. Biol. 2002; 64: 429-435.
  24. Rosengren A.T., Nyman T.A., Lashesman R. Proteonic profiling of interleukine 12 treated human T-helper cells. Proteomics 2005; 5(12): 3137-3141.
  25. Etz H., Minh D.B., Henics T., Dryla A., Winkler B., Triska C. et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 2002; 99(10): 6573-6578.
  26. Kuklin N.A., Clark D.J, Secore S., Cook J., Cope L.D, McNeely T. et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 2006; 74(4): 2215-2223.
  27. Torres V.J., Pishchany G., Humayun M., Schneewind O., Skaar E.P. Staphylococcus aureus IsdB is a hemoglobin receptor required for heme iron utilization. J. Bacteriol. 2006; 188(24): 8421-8429.
  28. Intercell in trouble as Merck stops MRSA vaccine trial. World News, 09.06.2011.
  29. Stranger-Jones Y.K., Bae T., Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 2006; 103(45): 16942-16947.
  30. Posey J.E., Gherardini F.C. Lack of a role for iron in the Lyme disease pathogen. Science 2000; 288(5471): 1651-1653.
  31. Skaar E.P., Schneewind O. Iron-regulated surface determinants (Isd) of Staphylococcus aureus: stealing iron from heme. Microbes Infect. 2004; 6(4): 390-397.
  32. Stauff D.L., Skaar E.P. The heme sensor system of Staphylococcus aureus. Contrib. Microbiol. 2009; 16: 120-135.
  33. Lin L., Ibrahim A.S., Xin X., Farber J. M., Avanesian V., Baquir B. et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 2009; 5(12): e1000703. doi: 10.1371/journal.ppat.1000703.
  34. Spellberg B., Daum R. A new view on development of Staphylococcus aureus vaccine. Hum. Vaccin. 2010; 6(10): 857-859.
  35. Spellberg B., Ibrahim A.S., Yeaman M.R., Lin L., Fu Y., Avanesian V. et al. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect. Immun. 2008; 76(10): 4574-4580.
  36. McDevitt D., Francois P., Vaudaux P., Foster T.J. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol. Microbiol. 1994; 11(2): 237-248.
  37. Foster T.J., Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 1998; 6(12): 484488.
  38. Vernachio J.H., Bayer A.S., Ames B., Bryant D., Prater B.D., Syribeys PJ. et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob. Agents Chemother. 2006; 50(2): 511-518.
  39. DeJonge M., Burchfield D., Bloom B., Duenas M., Walker W., Polak M. et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 2007 151(3): 260-265.
  40. Patti J.M. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 2004; 22(Suppl 1): S39-S43.
  41. Weems J.J.Jr., Steinberg J.P., Filler S., Baddley J.W., Corey G.R., Sampathkumar P. et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2006; 50(8): 2751-2755.
  42. Foster T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005; 3(12): 948-958.
  43. DeLeo F.R., Otto M. An antidote for Staphylococcus aureus pneumonia? J. Exp. Med. 2008; 205(2): 271-274.
  44. Szmigielski S., Prevost G., Monteil H., Colin D.A., Jeljaszewicz J. Leukocidal toxins of staphylococci. Zentralbl Bakteriol. 1999; 289(2): 185-201.
  45. Wang R., Braughton K.R., Kretschmer D., Bach T.H., Queck S.Y., Li M. et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 2007; 13(12): 1510-1514.
  46. Ефремова В.Н., Егорова Н.Б., Масюкова С.А. Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции. Патент РФ № 2122862, 1998.
  47. Егорова Н.Б., Ефремова В.Н., Курбатова Е.А., Грубер И.М. Экспериментальная и клинико-иммунологическая оценка бесклеточной стафилококковой вакцины «Стафиловак». Журн. микробиол. 2008; (6): 102-108.
  48. Масюкова С.А., Гладько В.В., Устинов М.В., Владимирова Е.В., Тарасенко Г.Н., Сорокина Е.В. Бактериальные инфекции кожи и их значение в клинической практике дерматолога. Consilium medicum 2004; 6(3): 180-185.
  49. Сорокина Е.В. Бактериальные вакцины в терапии хронической пиодермии. Автореф. дис..канд. мед. наук. М., 2006.
  50. Кузьменко О.М., Злыгостев С.А., Михайлова Н.А., Грубер И.М., Ахматова Н.К., Егорова Н.Б. и др. Характеристика комплексов антигенов Staphylococcus aureus, полученных в различных условиях культивирования. Журн. микробиол. 2010; (2): 51-54.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##